BenzingaOctober 7, 2026 at 7:17 AM NY20 Days Ago
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
